Eloxx Pharmaceuticals, Inc.
ELOX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$12.80
KIRA · Stoqly’s AI analyst, in plain words
- Eloxx Pharmaceuticals, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- Eloxx Pharmaceuticals, Inc. lost $6.0M in fiscal 2025.
- Eloxx Pharmaceuticals, Inc. has $3.8M more cash than debt.
Market cap
$86.9M
P/E
—
Revenue
$0.0M
Net income
−$6.0M
Free cash flow
—
Operating margin
—
Eloxx Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$6.0M
No. It lost money last year.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Eloxx Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Legal name
- Eloxx Pharmaceuticals, Inc.
- CIK
- 0001035354
Eloxx Pharmaceuticals, Inc. · ELOX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $0.0M | $6.4M | $0.0M |
| Revenue growth | — | — | — | — | −100.0% |
| Operating margin | — | — | — | −38.8% | — |
| Net income | −$66.7M | −$36.1M | −$17.1M | −$3.1M | −$6.0M |
| Net margin | — | — | — | −49.4% | — |
| Diluted EPS | −$38.15 | −$16.65 | −$6.63 | −$0.84 | −$0.49 |
| Cash | |||||
| Cash from operations | −$35.0M | −$31.8M | −$14.3M | −$4.7M | −$6.3M |
| Capital expenditure | $0.1M | $0.1M | — | — | — |
| Free cash flow | −$35.1M | −$31.9M | — | — | — |
| Share count change | −95.6% | 23.9% | 18.7% | 46.2% | 228.5% |
| Debt and strength | |||||
| Cash and short-term investments | $42.3M | $19.2M | $1.1M | $0.1M | $4.8M |
| Debt incl. finance leases | $11.2M | $11.7M | $3.8M | $6.5M | $1.0M |
| Shareholders' equity | $22.4M | −$10.7M | −$22.6M | −$24.3M | −$11.9M |
| Current ratio | 4.4x | 0.9x | 0.1x | 0.1x | 0.3x |
| Returns and quality | |||||
| Return on equity | −409.2% | −615.2% | — | — | — |
| Return on tangible equity | −298.1% | — | — | — | — |
| Piotroski F-score | 4 | 1 | 1 | 4 | 2 |
| Altman Z'' | −21.1 | −54.6 | −704.8 | −382.8 | −209.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Eloxx Pharmaceuticals, Inc. · ELOX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $12.80 a share, the company is worth $86.9M.
Source: SEC EDGAR XBRL filings (CIK 0001035354). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.